SAB BIO Appoints Lucy To as Chief Financial Officer

Core Insights - SAB Biotherapeutics has appointed Lucy To as Chief Financial Officer, effective August 12, 2024, bringing over 18 years of investment banking and strategic operational expertise to the company [6] - The company is focused on developing SAB-142, a therapeutic aimed at delaying the onset and progression of type 1 diabetes (T1D), with top-line Phase 1 data expected by the end of 2024 [1][6] - SAB utilizes a novel immunotherapy platform that generates human immunoglobulins without the need for human donors, targeting serious unmet needs in immune and autoimmune disorders [2] Company Overview - SAB BIO is a clinical-stage biopharmaceutical company developing high-potency immunoglobulins (IgGs) to treat immune and autoimmune disorders [2] - The lead asset, SAB-142, employs a disease-modifying therapeutic approach to change the treatment paradigm for T1D [2] - The company’s DiversitAb™ drug development system leverages advanced genetic engineering to produce a diverse range of specifically targeted human IgGs [2] Leadership and Strategy - Lucy To's role will encompass corporate finance, corporate strategy, and broader strategic business relationships [6] - The company aims to deliver value to shareholders while transforming the landscape of T1D treatment [1]